Peptide Antagonists of Transient Receptor Potential Vanilloid Type Calcium Channel (TRPV6) as a Potential Therapeutic Agent for Multiple Myeloma
Overexpression of the calcium channel – Transient receptor potential vanilloid type (TRPV6) occurs in many epithelial type cancers  and hematological malignancy such as leukemia . However, no correlation of TRPV6 to the deadly bone marrow cancer, multiple myeloma, has been made so far. Recently, we have detected the strong expression of TRPV6 protein in the bone marrow of MM patients, and this interesting finding has led us to investigate the potential of TRPV6 as a therapeutic target for multiple myeloma in collaboration with Soricimed Biopharma Inc. that has synthesized novel peptide antagonists for TRPV6 namely Sor C-13 and Sor C-27. I propose that inhibition of TRPV6 using peptide antagonist is a potential treatment strategy for multiple myeloma. I will explore this idea in human multiple myeloma cell lines, human primary osteoclasts and in a humanized murine model.